Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages 308-316

  Candoni, Anna ^a   Toffoletti, Eleonora ^a   Gallina, Roberto ^a   Simeone, Erica ^a   Chiozzotto, Marianna ^a   Volpetti, Stefano ^a   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Chimerism; Minimal residual disease; RIC SCT; WT1

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; THIOTEPA; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; WT1 GENE;

ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS; YOUNG ADULT;

EID: 79953302166     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01251.x     Document Type: Article

References (32)

1. Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990: 60: 509.
2. Yang L, Han Y, Saurez F, Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007: 3: 1.
3. Miyagi T, Ahuja H, Kudota T et al. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia 1993: 7: 970.
4. Brieger J, Weidmann E, Fenchel K, Mitron PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994: 8: 2138.
5. Menssen HD, Renkl HJ, Rodeck U et al. Presence of Wilm's tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemia. Leukemia 1995: 9: 1060.
6. Inoue K, Ogawa H, Sonoda Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997: 89: 1405.
7. Inoue K, Ogawa H, Yamagami T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996: 88: 2267.
8. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994: 84: 3071.
9. Bergmann L, Miething C, Mourer U et al. High levels of Wilms' tumour gene (WT1), mRNA in acute myeloid leukemias are associated with a worse long term outcome. Blood 1997: 90: 1217.
10. Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebner U. WT1 gene expression in childhood leukemias. Acta Haematol 1999: 102: 72.
11. Cilloni D, Gottardi A, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002: 16: 2115.
12. Cilloni D, Messa F, Arruga F et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008: 93: 921.
13. Ommen HB, Nyvold GC, Breaendstrup K et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008: 141: 782.
14. Van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999: 13: 1901.
15. Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): a European LeukemiaNet Study. Blood 2007: 110: 542a.
16. Beillard E, Pallisgaard N, Van Der Velden VH et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003: 17: 2474.
17. Gabert J, Beillard E, Van Der Velden VH et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program. Leukemia 2003: 17: 2318.
18. Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. J Clin Oncol 2009: 27: 5195.
19. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia. J Clin Oncol 2003: 21: 4642.
20. Thiede C, Bornhauser M, Oelschlagel U et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001: 15: 293.
21. Bacher U, Zander AR, Haferlach T et al. Minimal residual disease diagnostic in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008: 42: 145.
22. Chung NG, Ausch V, Radich JP. The detection and significance of minimal residual disease in acute and chronic leukaemia. Tissue Antigens 2006: 68: 371.
23. Perez-Simon JA, Caballero D, Diez-Campelo M et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002: 16: 1423.
24. Cilloni D, Gottardi E, Fava M et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker of minimal residual disease detection. Blood 2003: 102: 773.
25. Weisser M, Kern W, Rauhut S et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukaemia. Leukemia 2005: 19: 1416.
26. Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003: 101: 1698.
27. Candoni A, Tiribelli M, Toffoletti E et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008: 82: 61.
28. Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008: 42: 297.
29. Huisman C, De Veger RA, De Vries L, Tilanus MG, Verdonck LF. Chimerism analysis within 6months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukaemia. Bone Marrow Transplant 2007: 39: 285.
30. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukaemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2007: 43: 11.
31. Dominetto A, Pozzi S, Miglino M et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007: 109: 5063.
32. Ogawa H, Tsuboi A, Oji Y et al. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of monitoring of minimal residual disease by WT1 assay. Bone Marrow Transplant 1998: 21: 525.